Sao Paolo – Brazilian health experts have reportedly signified dissatisfaction with the China’s Sinovac anti-Covid vaccine after it emerged that it had an efficacy rate of only 50.4 percent.
According to a report by Singapore’s South China Morning Post (SCMP), the Sao Paolo government had previously said that CoronaVac vaccine (manufactured by the Beijing-based Sinovac pharmaceutical firm) was 78 percent effective in preventing mild cases of Covid19 and 100 percent effective against severe and moderate infections.
But in revised data submitted to Brazil’s health regulator, the Sao Paolo-funded Butantan Institute, which is reportedly conducting Stage 3 clinical trials for CoronaVac, listed an efficacy rate of 50.4 percent, which is significantly less effective than earlier suggested.
The numbers were confirmed during a press conference last week by officials of the research institute.
Nevertheless, Butantan said the public should not focus on the new efficacy rate.